Amprenavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Drug reference
Maraviroc
Antiretroviral · Antiviral
Also known as MVC, Celsentri
AntiretroviralAntiviral
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Manufacturer advises use only if potential benefit outweighs risk—toxicity in animal studies.
FDA category + note
Top interactionssee all 12 →
- AmprenavirSevereDatabaseDDInter
- ApalutamideSevereDatabaseDDInter
- AtazanavirSevereDatabaseDDInter
- BoceprevirSevereDatabaseDDInter
Mechanism
Maraviroc is an antagonist of the CCR5 chemokine receptor. It acts as an allosteric, noncompetitive antagonist that binds to the CCR5 receptor on the patient's CD4 cells. This binding denies HIV entry into the host cell.
Indications
CCR5-tropic HIV infection in combination with other antiretroviral drugs in patients previously treated with antiretroviralsHIV-infected adults who have baseline evidence of predominantly CCR5-tropic virusHIV (added to optimized background therapy in patients who have already been treated with several regimens and who have CCR5-tropic HIV infection; tropism must be proven)
Dosing
- Adult
- 300 mg twice daily by mouth
Pharmacokinetics
Onset
Active orally
Bioavailability
23–33%
Side effects
Common
Abdominal painAnaemiaDecreased appetiteAstheniaDepressionDiarrhoeaFlatulenceHeadacheInsomniaNauseaRashorthostatic hypotension
Serious
- Hyperbilirubinaemia
- Increased risk of infection
- Myopathy
- Postural hypotension
- Proteinuria
- Renal failure
- Seizure
- Angina pectoris
- Granulocytopenia
- Hepatic disorders
- Metastases
- Neoplasms
- Pancytopenia
- Severe cutaneous adverse reactions (SCARs)
- Fever
- Hypersensitivity
- Immune reconstitution inflammatory syndrome
- Organ dysfunction
- Osteonecrosis
- Hepatotoxicity
- serious hepatotoxicity with allergic features
- impaired immune surveillance (concern)
- increased risk of infection/malignancy (concern)
Pregnancy & lactation
Pregnancy
Manufacturer advises use only if potential benefit outweighs risk—toxicity in animal studies.
Drug interactions
Apalutamide
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Atazanavir
Severe
Database
Drug interaction classified as: metabolism.
Source: DDInter
Boceprevir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Carbamazepine
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Ceritinib
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Clarithromycin
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Conivaptan
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Darunavir
Severe
Database
Increased maraviroc concentrations.
The maraviroc dose should be reduced to 150 mg twice daily when combined with darunavir.
Source: DDInter
Delavirdine
Severe
Database
Clinical effect not specified
Source: DDInter
Efavirenz
Severe
Database
Clinical effect not specified
Source: DDInter
Enzalutamide
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other Antiretroviral drugs
Ask House about Maraviroc
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team